

Edgar Filing: PFIZER INC - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02 Results of Operations and Financial Condition.

On April 17, 2008, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2008. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit 99 -	Press Release of Pfizer Inc. dated April 17, 2008, reporting Pfizer's financial results for the first quarter of 2008. Exhibit 99 is deemed to be “filed” under the Securities Exchange Act of 1934 in this Current Report on Form 8-K.
--------------	---

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

By: /s/ Margaret M. Foran

Margaret M. Foran

Title: Senior Vice President-Corporate Governance,
Associate General Counsel and Corporate Secretary

Dated: April 17, 2008

EXHIBIT INDEX

Exhibit No. Description

99 Press Release of Pfizer Inc. dated April 17, 2008, reporting Pfizer's financial results for the first quarter of 2008.